Category: Markets
Published: 2026-07-16T11:26:32.000Z
Merck's oral PCSK9 inhibitor, Lipfendra (enlicitide), has received FDA approval for adults with high cholesterol levels. The drug aims to reduce low-density lipoprotein cholesterol, commonly known as bad cholesterol. This approval provides a new treatment option for managing high cholesterol.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.